Sanofi and Regeneron Take Aim on Amgen IL-4 Receptor Patent

Sanofi and Regeneron Take Aim on Amgen IL-4 Receptor Patent


This week Sanofi-Aventis and Regeneron Pharmaceuticals took aim at Amgen's U.S. Patent No. 8,679,487 on two fronts, filing a declaratory judgment action in district court and a petition for inter partes review in the U.S. Patent & Trademark Office.



from Biotech News